TL;DR
Researchers have identified a novel mechanism by which non-small cell lung cancer (NSCLC) cells develop resistance to EGFR inhibitors. Loss of the epigenetic factor SUV420H2 leads to the upregulation of a long non-coding RNA (LINC01510), which in turn promotes the expression of the oncogene MET, a key player in bypass signaling pathways that drive resistance. This discovery sheds light on a new avenue for overcoming treatment resistance in NSCLC.
What Problem Does This Paper Address?
Epidermal growth factor receptor (EGFR) inhibitors are a cornerstone of treatment for many non-small cell lung cancer (NSCLC) patients with specific EGFR alterations. However, a significant challenge is the development of resistance to these therapies, often within a year of treatment. While some resistance mechanisms are understood (like secondary EGFR mutations), many others, particularly those involving bypass signaling pathways that allow cancer cells to survive without relying on EGFR, remain poorly understood. This lack of understanding hinders the development of more effective and durable treatments. This paper aims to uncover novel mechanisms driving EGFR inhibitor resistance in NSCLC, focusing on the understudied area of bypass track activation.
Methods
The study employed a multi-pronged approach to identify and validate the role of SUV420H2 in EGFR inhibitor resistance:
- Genome-wide CRISPR-Cas9 Knock-out Screen: This high-throughput screening method was used to identify genes whose loss confers resistance to erlotinib in NSCLC cells. EKVX cells, known to be erlotinib-sensitive, were engineered to express Cas9 and then infected with a lentiviral sgRNA library targeting thousands of genes. Cells were then exposed to erlotinib, and sgRNAs enriched in resistant cells were identified.
- Validation Assays: Once potential candidates were identified, various experimental techniques were used to confirm their roles. These included:
- qRT-PCR: To measure mRNA expression levels of genes like KMT5C (which encodes SUV420H2), MET, and LINC01510.
- Western Blotting: To assess protein levels of MET and H4K20me3 (a modification catalyzed by SUV420H2).
- Immunofluorescence: To visualize the localization and levels of H4K20me3 within cells.
- Cell Viability Assays (SRB assay): To determine the GI50 (concentration of drug that inhibits cell growth by 50%) of erlotinib and other EGFR inhibitors in cells with altered SUV420H2 expression.
- Live Cell Imaging (Incucyte): To quantify cell proliferation in response to drug treatment.
- ChIP-qPCR: To investigate the binding of H4K20me3 to specific genomic regions, particularly around the LINC01510 and MET loci.
- siRNA-mediated Knockdown: To reduce the expression of LINC01510 or MET and assess the impact on erlotinib resistance.
- Overexpression Studies: To investigate the effect of increasing SUV420H2 levels on drug sensitivity.
- Bioinformatic Analysis: Publicly available datasets from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) projects were analyzed to assess gene expression correlations in NSCLC patient samples.
Datasets
- NCI-60 Cell Line Panel: Used for initial characterization of erlotinib sensitivity in EKVX cells.
- The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) projects: Publicly available datasets used for bioinformatic analysis of KMT5C, LINC01510, and MET expression levels in NSCLC patient samples and normal tissues.
- GSE59316 (Human lung fibroblast cell line IMR90 ChIP-seq data): Used to analyze H4K20me3 modification patterns.
Key Insights and Ideas
- SUV420H2 as a Gatekeeper of EGFRi Sensitivity: The study identifies SUV420H2, an epigenetic factor, as a crucial regulator of sensitivity to EGFR inhibitors in NSCLC. Its loss is a significant driver of resistance.
- The LINC01510-MET Axis: The research uncovers a novel signaling pathway where loss of SUV420H2 leads to the upregulation of the long non-coding RNA LINC01510, which in turn promotes the transcription of the oncogene MET. This LINC01510-MET axis is a key bypass mechanism that allows cancer cells to evade EGFR inhibition.
- H4K20me3 as the Mediator: SUV420H2's function in repressing gene expression is mediated through the trimethylation of histone H4 lysine-20 (H4K20me3). Loss of SUV420H2 results in reduced H4K20me3, leading to the de-repression of LINC01510.
- Specificity of SUV420H2's Role: The study suggests that SUV420H2's role in resistance is not global but rather specific to EGFR inhibitors, as mutant cells were unaffected by cisplatin.
Key Results
- A genome-wide CRISPR-Cas9 screen identified SUV420H2 as a top hit conferring erlotinib resistance upon its loss.
- Loss of SUV420H2 in NSCLC cells led to a 5.4 to 11.7-fold increase in resistance to erlotinib.
- SUV420H2 mutant cells exhibited resistance to multiple EGFR inhibitors, including erlotinib, gefitinib, afatinib, and osimertinib.
- Loss of SUV420H2 resulted in a significant upregulation of LINC01510 and MET transcript and protein levels.
- Knockdown of LINC01510 or MET in SUV420H2 mutant cells partially re-sensitized them to erlotinib.
- Overexpression of SUV420H2 in resistant cells partially restored sensitivity to EGFR inhibitors.
- Bioinformatic analysis revealed a negative correlation between KMT5C (SUV420H2) and MET/LINC01510 expression in NSCLC patient samples.
- ChIP-qPCR experiments showed that H4K20me3 modification is localized to the gene body of LINC01510, suggesting SUV420H2 regulates LINC01510 expression via this modification.
Limitations and Future Work
- Specificity of SUV420H2: While the study suggests specificity for EGFRi, further evaluation of SUV420H2's role in sensitizing resistant cells to other chemotherapeutic and targeted agents is warranted.
- Other Oncogenes: The authors acknowledge that other oncogenes regulated by SUV420H2 may contribute to the resistance phenotype, and these candidates require further investigation.
- Genomic Stability: The role of SUV420H2 and H4K20me3 in maintaining genomic stability and their dynamics in response to EGFRi warrants further study.
- Upstream Regulators: The study mentions that other upstream regulators of SUV420H2, such as HP1, might also play a role in drug resistance, suggesting avenues for future research.
Summary updated